Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with
mCRPC who have progressed on prior approved systemic therapies for their castrate resistant
disease (one of which must be enzalutamide or abiraterone).